The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Kaposi Sarcoma–Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment
Open accessAbstract
Kaposi sarcoma associated herpesvirus (KSHV), a γ2-herpesvirus, also known as human herpesvirus-8, is the etiologic agent of three virally associated tumors: Kaposi sarcoma, a plasmablastic form of multicentric Castleman disease (KSHV-MCD), and primary effusion lymphoma. These malignancies are predominantly seen in people with acquired immunodeficiencies, including acquired immunodeficiency syndrome and iatrogenic immunosuppression in the setting of organ transplantation, but can also develop in the elderly. Kaposi sarcoma (KS) is most frequent in regions with high KSHV seroprevalence, such as sub-Saharan Africa and some Mediterranean countries. In the era of combination antiviral therapy, inflammatory manifestations associated with KSHV-infection, including KSHV-MCD, a recently described KSHV-associated inflammatory cytokine syndrome and KS immune reconstitution syndrome also are increasingly appreciated. Our understanding of viral and immune mechanisms of oncogenesis continues to expand and lead to improved molecular diagnostics, as well as novel therapeutic strategies that employ immune modulatory agents, manipulations of the tumor microenvironment, virus-activated cytotoxic therapy, or agents that target interactions between specific virus-host cell signaling pathways. This review focuses on the epidemiology and advances in molecular and clinical research that reflects the current understanding of viral oncogenesis, clinical manifestations, and therapeutics for KSHV-associated tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, two other HHV8-associated neoplasms, primary effusion lymphoma111 and Castleman disease112, have also been shown to be responsive to treatment with thalidomide analogues.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells
Guasparri, I., Keller, S. A., & Cesarman, E. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031467 · Cited by 325
RetractedIdentification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,608
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
Cesarman, E., Chang, Y., Moore, P. S., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321802 · Cited by 2,853
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,296
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.-L., Schröter, M., et al. (1997) · Nature · doi:10.1038/386517a0 · Cited by 1,316
Nador, R., Cesarman, E., Chadburn, A., et al. (1996) · Blood · doi:10.1182/blood.v88.2.645.bloodjournal882645 · Cited by 1,172
Moore, P. S., & Chang, Y. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321801 · Cited by 1,095
Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.
Friedman‐Kien, A. E., Laubenstein, L. J., Marmor, M. F., Hymes, K. B., Green, J., Ragaz, A., Gottleib, J., Muggia, F. M., Demopoulos, R. I., & Weintraub, M. R. (1981) · PubMed · Cited by 1,091
Research works printed but not linked: 1
- 2012, Estimated HIV incidence in the United States, 2007–2010, HIV Surveillance Supplemental Report
Cited by
Sorted by citations
Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3812 · Cited by 138
Self-citationCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Metadata
- Authors
- Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R.
- Affiliations
- National Cancer Institute (US)
- Corresponding author
- Yarchoan, Robert
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 42
- Issue
- 2
- Pages
- 223-246
- ISSN
- 0093-7754 (ISSN-L)
- PMC
- PMC6309362
- OpenAlex
- W2154435586
- Cited by
- 155
- References
- 209
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 13 · 2018: 10 · 2017: 27 · 2016: 25 · 2015: 8
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Seminars in Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, public-domain)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010885, ZIABC010888)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Keywords
- Kaposi's sarcoma-associated herpesvirus, human herpesvirus 8, Kaposi's sarcoma, multicentric Castleman disease, primary effusion lymphoma, viral oncogenesis, immunodeficiency, HIV/AIDS, organ transplantation, antiviral therapy, tumor microenvironment, immunomodulatory therapy, molecular diagnosis
- MeSH terms
- Herpesviridae Infections, Humans, Neoplasms, Seroepidemiologic Studies, Herpesvirus 8, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
